Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Dye May Diagnose Early Alzheimer's

By HospiMedica staff writers
Posted on 07 Sep 2005
Investigators have developed a new dye that may provide a noninvasive early diagnosis of Alzheimer's disease (AD), a finding that could also help in tracking the progression of the disease and in studying the effectiveness of new treatments to stop it.

Currently, clinicians can only make a definitive diagnosis of AD--currently the fourth-leading cause of death in the United States--through a postmortem autopsy of the brain. More...
"Before you can cure Alzheimer's, you have to be able to diagnose it and monitor its progress very precisely,” commented Dr. Timothy Swager, lead investigator of the study and a professor in the department of chemistry of the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA).

To accomplish this task, Dr. Swager and worked with researchers at Massachusetts General Hospital (Boston, MA, USA) and the University of Pittsburgh (PA, USA) to develop a contrast agent that would first bind to the protein deposits, or plaques, in the brain that cause AD, and then fluoresce when exposed to radiation in the near-infrared range. The new dye could provide direct imaging of Alzheimer's plaques through a patient's skull.

Some of the first noninvasive methods for detecting AD involved agents labeled with radioactive elements that could enter the brain and target disease plaque for imaging with positron emission tomography (PET) imaging. However, these techniques were costly and limited by the short working lifetime of the labeled agents.

Dr. Swager and coworkers developed the new dye, called NIAD-4, through a targeted design process based on a set of certain requirements, including the ability to enter the brain rapidly upon injection, attach to amyloid plaques, absorb and fluoresce radiation in the right spectral range, and provide a clear contrast between the plaques and the surrounding tissue. The dye provided sharp visual images of amyloid brain plaques in living mice with specially prepared cranial windows.

To make the technique truly noninvasive, researchers must additionally refine the dye so it fluoresces at a slightly longer wavelength, closer to the infrared (IR) region. Light in the near-IR range can penetrate living tissue well enough to make brain structures visible.

The new dye was developed as part of a wider effort in sensing technology at MIT's Institute for Soldier Nanotechnologies. The study was published in the Aug. 26, 2005, issue of the journal Angewandte Chemie.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.